Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.44 USD
+0.03 (7.29%)
Updated Apr 25, 2024 03:12 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Panbela Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -25.26 | -34.93 | -10.14 | -4.77 | -6.20 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 2.08 |
Net Change from Assets/Liabilities | -0.65 | 0.56 | 2.14 | -0.19 | 0.19 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.66 | 19.10 | 1.29 | 1.10 | 1.20 |
Net Cash From Operating Activities | -25.25 | -15.28 | -6.70 | -3.85 | -2.74 |
Property & Equipment | 0.40 | -0.66 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | -0.54 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.40 | -0.66 | -0.54 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 27.80 | 5.35 | 10.10 | 11.20 | 3.16 |
Issuance (Repayment) of Debt | -1.65 | 0.00 | 0.00 | -0.86 | -0.19 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.10 | 0.81 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 26.14 | 5.35 | 10.10 | 10.44 | 3.78 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | -0.01 | -0.02 | 0.00 |
Net Change In Cash & Equivalents | 1.29 | -10.58 | 2.85 | 6.57 | 1.04 |
Cash at Beginning of Period | 1.29 | 11.87 | 9.02 | 2.45 | 1.41 |
Cash at End of Period | 2.58 | 1.29 | 11.87 | 9.02 | 2.45 |
Diluted Net EPS | -316.52 | NA | NA | NA | NA |
Fiscal Year End for Panbela Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -25.26 | -18.79 | -10.95 | -5.11 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | -0.65 | -3.85 | -5.16 | -4.86 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.66 | 0.47 | 0.62 | 0.22 |
Net Cash From Operating Activities | NA | -25.25 | -22.17 | -15.49 | -9.75 |
Property & Equipment | NA | 0.40 | 0.40 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.40 | 0.40 | 0.00 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 27.80 | 23.05 | 23.07 | 15.36 |
Issuance (Repayment) of Debt | NA | -1.65 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | -1.65 | -1.65 | -1.65 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.01 | -0.01 | -0.01 | 0.00 |
Net Cash from Financing Activities | NA | 26.14 | 21.39 | 21.41 | 13.70 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 1.29 | -0.38 | 5.92 | 3.95 |
Cash at Beginning of Period | NA | 1.29 | 1.29 | 1.29 | 1.29 |
Cash at End of Period | NA | 2.58 | 0.91 | 7.21 | 5.24 |
Diluted Net EPS | NA | 286.67 | -53.80 | -159.00 | -390.39 |